Basaloid squamous carcinoma of the oral cavity: report of 2 cases and study of AgNOR, PCNA, p53, and MMP expression.
Basaloid squamous carcinoma (BSC) is an uncommon aggressive variant of squamous cell carcinoma (SCC) with a predilection for the head and neck. In the English literature, approximately 40 cases of BSC in the oral cavity have been described. In this study, the clinicopathologic features of 2 cases of BSC affecting the buccal mucosa are reported. In addition, we compare the proliferative and invasive potential of BSC cells with that of poorly differentiated SCC cells matched for age, sex, site, and TNM status. Proliferative activity was studied through use of the argyrophilic nuclear organizer region (AgNOR) method and immunohistochemical quantification of proliferating cell nuclear antigen (PCNA). The invasive potential was evaluated through use of the semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR) for matrix metalloproteinases (MMPs). Alterations of p53 were also investigated through use of immunohistochemistry. The tumors showed many clinical and histopathologic similarities to tumors in cases previously reported. The AgNOR and PCNA indices were significantly higher in the 2 cases of BSC than in the cases of SCC. Immunostaining for p53 protein showed a higher percentage of positive cells and more intense staining in the BSC tissues than in the SCC tissues. RT-PCR studies clearly demonstrated that the expression of MMP-1, MMP-2, and MMP-9 was higher in cells from BSCs than in cells from SCCs. Taken together, the data described here are compatible with the concept that BSC has a more aggressive biologic behavior than conventional SCC.
Coletta
R D
RD
Department of Oral Surgery, University of Campinas Dental School, Caixa Postal 52, 13414-018 Piracicaba, São Paulo, Brazil.
Cotrim
P
P
Vargas
P A
PA
Villalba
H
H
Pires
F R
FR
de Moraes
M
M
de Almeida
O P
OP
D002281:Carcinoma, Basosquamous / Q000201:enzymology / Q000473:pathology*; D002294:Carcinoma, Squamous Cell / Q000473:pathology; D016022:Case-Control Studies; D002455:Cell Division; D004396:Coloring Agents; D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000032:analysis; D020778:Matrix Metalloproteinase 2 / Q000032:analysis; D020780:Matrix Metalloproteinase 9 / Q000032:analysis; D020782:Matrix Metalloproteinases / Q000032:analysis*; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000201:enzymology / Q000473:pathology*; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009697:Nucleolus Organizer Region / Q000648:ultrastructure*; D018809:Proliferating Cell Nuclear Antigen / Q000032:analysis*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012835:Silver Nitrate; D016159:Tumor Suppressor Protein p53 / Q000032:analysis*
D004396:Coloring Agents; D018809:Proliferating Cell Nuclear Antigen; D016159:Tumor Suppressor Protein p53; D012835:Silver Nitrate; D020782:Matrix Metalloproteinases; D020778:Matrix Metalloproteinase 2; D020780:Matrix Metalloproteinase 9; D020781:Matrix Metalloproteinase 1